ArticleNutrition journal2025
Urinary enterolignan concentrations and cardiometabolic risk biomarkers in pregnant US women.
Article in Nutrition journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrior evidence suggests that dietary lignans may mitigate inflammation, attenuate insulin resistance, and improve blood lipids. Little is known about the effects of lignans in pregnant women who are at elevated risk of glucose and lipid abnormalities, partially due to increase in estrogen levels during pregnancy. This study was designed to investigate the association between dietary lignan intake, measured as urinary enterolignans (enterodiol and enterolactone), with blood biomarkers of cardiometabolic risks in pregnant women. RESEARCH DESIGN AND
methodsWe analyzed data from 480 pregnant women who participated in the National Health and Nutrition Examination Survey (NHANES) 1999-2010 and had data for urinary enterolignan concentrations. Multivariable linear regression analyses were used to examine the association between urinary enterolignan concentrations and cardiometabolic risk biomarkers. Cardiometabolic risk markers were log-transformed and geometric means were calculated by quartiles of urinary enterolignan concentrations.
resultsHigher urinary enterolignan concentrations were associated with a more beneficial cardiometabolic profile: comparing women in the highest versus lowest quartiles of total enterolignan concentrations, high-density lipoprotein cholesterol (HDL-C) was 62 versus 54 mg/dL (P for trend = 0.01); triacylglycerol (TG) was 141 versus 171 mg/dL (P for trend = 0.004); TG/HDL-C ratio was 2.3 versus 3.2 (P for trend = 0.001); Total cholesterol (TC)/HDL-C ratio was 3.4 versus 3.9 (P for trend = 0.03); C-reactive protein (CRP) was 0.4 versus 0.7 mg/dL (P for trend = 0.01); and fasting insulin was 7.7 versus 13.9 μU/mL (P for trend < 0.0001).
conclusionsLignan intake may have favorable effects on cardiometabolic risk markers in pregnant women. KEY MESSAGES: The results of our study showed that urinary excretion of enterolignans were inversely associated with cardiometabolic risk markers in pregnant women. These findings support further investigation on the role of lignans in modifying lipid and glucose metabolism. Given the high prevalence of maternal insulin resistance and hyperlipidemia and its serious health consequences for both women and their offspring, the use of lignans, if demonstrated to be efficacious, could provide a cost-effective option for curbing this epidemic by prevention and early treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.